Gao Qi is a research assistant at Saw Swee Hock School of Public Health, National University of Singapore in collaboration with MIDAS. Research fields include framework construction of health innovation process, early health technology assessment, and traditional health technology assessment. Interested in health policy effects and health innovatio

Ryan Jonathan Sitanggang is an International Cooperation Officer (ICO) at the International Unit of the HITAP Foundation. He works on strengthening HTA networks and systems across Asia through initiatives such as the Asia HTA Registry, the HTAsiaLink Strategic Plan, and regional capacity-building. His role includes managing partnerships, coordinati

Executive Summary Digital health in Korea encompasses a wide range of technologies and services yet lacks a clear legal definition. The Korea Institute for Industrial Economics & Trade (KIET) classifies digital health into hardware, software, and service categories, reflecting the diverse lan

การพัฒนาและประเมินชุดสิทธิประโยชน์ (ที่ไม่ใช่ยา) เพื่อสนับสนุนการเข้าถึงบริการสุขภาพของประเทศไทย เป็นการดําเนินงานที่เป็

66183067HM017L0health economic evaluation,health technology assessment,medical innovation,research and development,target product profiles

The Health Intervention and Technology Assessment Program Foundation (HITAP) establishes the Global Research Unit (GRU), a new team created to strengthen evidence-informed policymaking in Thailand and internationally. Why GRU Matters Health technology assessment (HTA) h

COVID-19 has shown that irresepctive of national borders, the infectious disease brings multi-dimensional challenges requiring concerted global and regional efforts to address it. In contrast to the European Union and the African Union, the Association of Southeast Asian Nations (ASEAN), the regional cooperation body in Southeast Asia, has had no e

Management of advanced prostate cancer, particularly in cases of metastatic castration-resistant prostate cancer (mCRPC), typically involves first-line treatment with the chemotherapeutic agent docetaxel. Nevertheless, disease progression following docetaxel therapy remains a major challenge, as there are currently no therapeutic options listed in

67194067MU033L0